Evon, Donna M. http://orcid.org/0000-0002-1414-1846
Lin, Hsing-Hua S.
Khalili, Mandana
Wahed, Abdus S.
Yim, Colina
Fontana, Robert J.
Hoofnagle, Jay H.
,
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK082843, U01-DK082863, U01-DK082864, U01-DK082866, U01-DK082867, U01-DK082871, U01-DK082872, U01-DK082874, U01-DK082919, U01-DK082923, (U01-DK082927, U01-DK082943, U01-DK082944)
Article History
Received: 24 June 2023
Accepted: 5 September 2023
First Online: 7 October 2023
Declarations
:
: Donna Evon has received research grant funding (to her institution) from Gilead Sciences Inc and Merck Sharp and Dohme. Mandana Khalili received research grant funding (to her institution) from Gilead Sciences Inc and Intercept Pharmaceutical and has served as a scientific consultant for Gilead Science. Robert Fontana has received research support from Gilead, BMS, and Abbvie and provides consulting to Alynam. Colina Yim has received speaker’s honorarium from Abbvie Canada, and consulting fees from Abbvie Canada and Lupin Pharma Canada. Hsing-Hua S. Lin, Abdus S. Wahed, and Jay H. Hoofnagle have no conflict of interests to disclose.